[Effect of etmozin on thrombocyte aggregation capacity].
It was shown in in vitro experiments that etmozin at a concentration of 100 micrograms/ml significantly suppressed (by 21%) platelet aggregation induced by ADP, but it had no effect on platelet aggregation induced by arachidonic acid. In in vivo experiments etmozin was found to cause a marked suppression of tendon collagen-induced platelet aggregation in the doses 2-5 mg/kg having antiarrhythmic activity. Under suppressed platelet aggregation induced by indomethacin, the prostaglandin biosynthesis blocker etmozin displayed no antiaggregation effect. It is suggested that etmozin effects on ADP release from platelets play the main role in the mechanism of its antiaggregation action.
D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000494:pharmacology*; D016718:Arachidonic Acid; D001095:Arachidonic Acids / Q000494:pharmacology; D002415:Cats; D004305:Dose-Response Relationship, Drug; D066298:In Vitro Techniques; D007213:Indomethacin / Q000494:pharmacology; D016293:Moricizine; D010640:Phenothiazines / Q000494:pharmacology*; D010974:Platelet Aggregation / Q000187:drug effects*; D011817:Rabbits
D000889:Anti-Arrhythmia Agents; D001095:Arachidonic Acids; D010640:Phenothiazines; D016718:Arachidonic Acid; D016293:Moricizine; D007213:Indomethacin
Vliianie étmozina na agregatsionnuiu sposobnost' trombotsitov.